Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 2 · 40%Low 2 · 40%Moderate 0 · 0%High 0 · 0%

CLOZAPINE + RISPERIDONE vs CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010)

Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia

1 finding from 1 review

Clozapine combined with different antipsychotic drugs for treatment‐resistant schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

Mental state: No 20% response (as defined by PANSS/BPRS total change) · patients with schizophrenia

RISPERIDONE + CLOZAPINE showed no clear difference in mental state: no clinically significant response in psychotic… compared with PLACEBO + CLOZAPINE (low certainty).

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.15 [0.93, 1.42]
2 studies · 98 participants
Low

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
1.13 [0.53, 2.42]
3 studies · 167 participants
Very low

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia

RISPERIDONE + CLOZAPINE showed no clear difference in global state: no significant clinical improvement ‐ CGI short term compared with PLACEBO + CLOZAPINE (low certainty).

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.12 [0.87, 1.44]
1 study · 68 participants
Low

CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Risperidone versus placebo for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found